The expression of ERα, ERβ and PR in lobular carcinoma in situ of the breast determined using laser microdissection and real-time PCR

Histopathology

Volumn 54, Issue 4, 2009, Pages 419-427

  Green, Andrew R ^a   Young, Peter ^a   Krivinskas, Sophie ^a   Rakha, Emad A ^a   Claire Paish, E ^a   Powe, Desmond G ^a   Ellis, Ian O ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Immunohistochemistry; Laser microdissection; Lobular carcinoma in situ; Oestrogen receptor; Real time PCR

Indexed keywords

ERBETA1 GENE; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ESTROGEN RECEPTOR BETA1; ESTROGEN RECEPTOR BETA2; MESSENGER RNA; PROGESTERONE RECEPTOR; UNCLASSIFIED DRUG; PRIMER DNA; RNA;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; BREAST LOBULAR CARCINOMA IN SITU; CANCER INVASION; CONTROLLED STUDY; DISEASE PREDISPOSITION; FEMALE; GENE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LASER MICRODISSECTION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; BREAST TUMOR; CARCINOMA IN SITU; CASE CONTROL STUDY; GENETICS; LASER; LUNG CARCINOMA; METABOLISM; MICRODISSECTION; PATHOLOGY; POLYMERASE CHAIN REACTION;

BASE SEQUENCE; BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, LOBULAR; CASE-CONTROL STUDIES; DNA PRIMERS; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; LASERS; MICRODISSECTION; NEOPLASM INVASIVENESS; POLYMERASE CHAIN REACTION; RECEPTORS, PROGESTERONE; RNA, MESSENGER; RNA, NEOPLASM;

EID: 62149119528     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2009.03233.x     Document Type: Article

References (36)

1. Frykberg ER. Lobular carcinoma in situ of the breast. Breast J 1999 5 296 303.
2. Page DL, Kidd TE Jr., Dupont WD, Simpson JF, Rogers LW. Lobular neoplasia of the breast: higher risk for subsequent invasive cancer predicted by more extensive disease. Hum. Pathol. 1991 22 1232 1239.
3. Prall OW, Rogan EM, Sutherland RL. Estrogen regulation of cell cycle progression in breast cancer cells. J. Steroid Biochem. Mol. Biol. 1998 65 169 174.
4. Mosselman S, Polman J, Dijkema R. ER beta: identification and characterization of a novel human estrogen receptor. FEBS Lett. 1996 392 49 53.
5. Tremblay GB, Tremblay A, Copeland NG et al. Cloning, chromosomal localization, and functional analysis of the murine estrogen receptor beta. Mol. Endocrinol. 1997 11 353 365.
6. Kuiper GG, Carlsson B, Grandien K et al. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology 1997 138 863 870.
7. Lazennec G, Bresson D, Lucas A, Chauveau C, Vignon F. ER beta inhibits proliferation and invasion of breast cancer cells. Endocrinology 2001 142 4120 4130.
8. Shaw JA, Udokang K, Mosquera JM, Chauhan H, Jones JL, Walker RA. Oestrogen receptors alpha and beta differ in normal human breast and breast carcinomas. J. Pathol. 2002 198 450 457.
9. Skliris GP, Parkes AT, Limer JL, Burdall SE, Carder PJ, Speirs V. Evaluation of seven oestrogen receptor beta antibodies for immunohistochemistry, western blotting, and flow cytometry in human breast tissue. J. Pathol. 2002 197 155 162.
10. Speirs V, Carder PJ, Lane S, Dodwell D, Lansdown MR, Hanby AM. Oestrogen receptor beta: what it means for patients with breast cancer. Lancet Oncol. 2004 5 174 181.
11. Ogawa S, Inoue S, Watanabe T et al. Molecular cloning and characterization of human estrogen receptor betacx: a potential inhibitor of estrogen action in human. Nucleic Acids Res. 1998 26 3505 3512.
12. Iwase H, Zhang Z, Omoto Y et al. Clinical significance of the expression of estrogen receptors alpha and beta for endocrine therapy of breast cancer. Cancer Chemother. Pharmacol. 2003 52 (Suppl. 1 S34 S38.
13. Leygue E, Dotzlaw H, Watson PH, Murphy LC. Altered estrogen receptor alpha and beta messenger RNA expression during human breast tumorigenesis. Cancer Res. 1998 58 3197 3201.
14. Giri DD, Dundas SA, Nottingham JF, Underwood JC. Oestrogen receptors in benign epithelial lesions and intraduct carcinomas of the breast: an immunohistological study. Histopathology 1989 15 575 584.
15. Rudas M, Neumayer R, Gnant MF, Mittelbock M, Jakesz R, Reiner A. p53 protein expression, cell proliferation and steroid hormone receptors in ductal and lobular in situ carcinomas of the breast. Eur. J. Cancer 1997 33 39 44.
16. Middleton LP, Perkins GH, Tucker SL, Sahin AA, Singletary SE. Expression of ERalpha and ERbeta in lobular carcinoma in situ. Histopathology 2007 50 875 880.
17. Madjd Z, Pinder SE, Paish C, Ellis IO, Carmichael J, Durrant LG. Loss of CD59 expression in breast tumours correlates with poor survival. J. Pathol. 2003 200 633 639.
18. Putti TC, El-Rehim DM, Rakha EA et al. Estrogen receptor-negative breast carcinomas: a review of morphology and immunophenotypical analysis. Mod. Pathol. 2005 18 26 35.
19. Lehmann U, Kreipe H. Real-time PCR analysis of DNA and RNA extracted from formalin-fixed and paraffin-embedded biopsies. Methods 2001 25 409 418.
20. Palmieri C, Cheng GJ, Saji S et al. Estrogen receptor beta in breast cancer. Endocr. Relat. Cancer 2002 9 1 13.
21. Mohsin SK, O'Connell P, Allred DC, Libby AL. Biomarker profile and genetic abnormalities in lobular carcinoma in situ. Breast Cancer Res. Treat. 2005 90 249 256.
22. Abdel-Fatah TM, Powe DG, Hodi Z, Lee AH, Reis-Filho JS, Ellis IO. High frequency of coexistence of columnar cell lesions, lobular neoplasia, and low grade ductal carcinoma in situ with invasive tubular carcinoma and invasive lobular carcinoma. Am. J. Surg. Pathol. 2007 31 417 426.
23. Abdel-Fatah TM, Powe DG, Hodi Z, Reis-Filho JS, Lee AH, Ellis IO. Morphologic and molecular evolutionary pathways of low nuclear grade invasive breast cancers and their putative precursor lesions: further evidence to support the concept of low nuclear grade breast neoplasia family. Am. J. Surg. Pathol. 2008 32 513 523.
24. Roger P, Sahla ME, Makela S, Gustafsson JA, Baldet P, Rochefort H. Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors. Cancer Res. 2001 61 2537 2541.
25. Speirs V, Kerin MJ. Prognostic significance of oestrogen receptor beta in breast cancer. Br. J. Surg. 2000 87 405 409.
26. Jarvinen TA, Pelto-Huikko M, Holli K, Isola J. Estrogen receptor beta is coexpressed with ERalpha and PR and associated with nodal status, grade, and proliferation rate in breast cancer. Am. J. Pathol. 2000 156 29 35.
27. Leygue E, Dotzlaw H, Watson PH, Murphy LC. Expression of estrogen receptor beta1, beta2, and beta5 messenger RNAs in human breast tissue. Cancer Res. 1999 59 1175 1179.
28. Iwao K, Miyoshi Y, Ooka M et al. Quantitative analysis of estrogen receptor-alpha and -beta messenger RNA expression in human pancreatic cancers by real-time polymerase chain reaction. Cancer Lett. 2001 170 91 97.
29. Omoto Y, Kobayashi S, Inoue S et al. Evaluation of oestrogen receptor beta wild-type and variant protein expression, and relationship with clinicopathological factors in breast cancers. Eur. J. Cancer 2002 38 380 386.
30. Palmieri C, Lam EW, Mansi J et al. The expression of ER beta cx in human breast cancer and the relationship to endocrine therapy and survival. Clin. Cancer Res. 2004 10 2421 2428.
31. Kietz S, Thomsen JS, Matthews J, Pettersson K, Strom A, Gustafsson JA. The Ah receptor inhibits estrogen-induced estrogen receptor beta in breast cancer cells. Biochem. Biophys. Res. Commun. 2004 320 76 82.
32. Allred DC, Mohsin SK, Fuqua SA. Histological and biological evolution of human premalignant breast disease. Endocr. Relat. Cancer 2001 8 47 61.
33. Cui X, Schiff R, Arpino G, Osborne CK, Lee AV. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J. Clin. Oncol. 2005 23 7721 7735.
34. Lakhani SR, Audretsch W, Cleton-Jensen AM et al. The management of lobular carcinoma in situ (LCIS). Is LCIS the same as ductal carcinoma in situ (DCIS)? Eur. J. Cancer 2006 42 2205 2211.
35. Sorlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl Acad. Sci. USA 2001 98 10869 10874.
36. Abd El-Rehim DM, Ball G, Pinder SE et al. High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int. J. Cancer 2005 116 340 350.